Skip to main content
RDHL
NASDAQ Life Sciences

RedHill Acquires Commercialization Rights to Ferring's Rebyota and Clenpiq

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.902
Mkt Cap
$5.473M
52W Low
$0.57
52W High
$2.79
52W Position info
58% above low
Off High info
68% below high
Rel. Volume info
56× avg
Market data snapshot near publication time

RDHL sits 58% above its 52-week low of $0.57 on elevated volume (56× avg).

Summary

RedHill Biopharma has acquired commercialization rights to Ferring's Rebyota and Clenpiq, two FDA-approved gastrointestinal products. This is a transformative deal for the micro-cap company, which has been struggling with going concern warnings and dilutive financings. The acquisition adds two revenue-generating assets to RedHill's portfolio, potentially improving its financial outlook. The deal follows the recent sale of its Talicia stake to Apotex for $18M upfront, suggesting a strategic pivot toward commercial-stage products. The agreement has a 13-year initial term with automatic two-year renewals, a $12 million upfront payment, tiered royalties of 5% to 20% on net sales, capped sales milestones, and minimum annual purchase commitments for Rebyota during 2027 through 2029.

Updated with an SEC 6-K filing · What changed

Updates

  1. · SEC 6-K — The agreement has a 13-year initial term with automatic two-year renewals, a $12 million upfront payment, tiered royalties of 5% to 20% on net sales, capped sales milestones, and minimum annual purchase commitments for Rebyota during 2027 through 2029.

At the time of this announcement, RDHL was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.57 to $2.79. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

RDHL - Latest Insights

RDHL
Oct 07, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4981
Real-time Price: $0.3381 info
Change: -$0.160 (-32%) info
Market Cap: $3.111M info
RDHL
Sep 30, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.4797
Real-time Price: $0.3381 info
Change: -$0.1416 (-30%) info
Market Cap: $3.111M info
RDHL
Sep 01, 2026, 7:10 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.9195
Real-time Price: $0.3381 info
Change: -$0.5814 (-63%) info
Market Cap: $3.111M info
RDHL
Aug 31, 2026, 7:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $0.6303
Real-time Price: $0.3381 info
Change: -$0.2922 (-46%) info
Market Cap: $3.111M info
RDHL
Jul 28, 2026, 7:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.640
Real-time Price: $0.3381 info
Change: -$0.3019 (-47%) info
Market Cap: $3.111M info